Physician profile
Michael J Bunda
NPI 1912955451
$3,252.24
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $920 · 2020: $300 · 2021: $558 · 2022: $620 · 2023: $784 · 2024: $70.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $754 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $753.81 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $582.59 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $314.85 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $293.99 | 2019-2023 | |
| Amgen INC. | $260.19 | 2019-2023 | Repatha |
| Merck Sharp & Dohme LLC | $224.76 | 2021-2023 | Verquvo |
| Pfizer INC. | $206.58 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.69 | 2019-2023 | |
| Boston Scientific Corporation | $194.30 | 2019-2024 | Watchman Flx, Bodyguardian, Watchman |
| Actelion Pharmaceuticals US, INC. | $161.82 | 2023 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $157.00 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $144.82 | 2019-2023 | Lifevest |
| Abbott Laboratories | $62.97 | 2019-2021 | |
| Astellas Pharma US INC | $61.31 | 2019-2021 | |
| Esperion Therapeutics, INC. | $54.56 | 2021 | |
| Amarin Pharma, INC. | $50.53 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $44.78 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $43.68 | 2019-2023 | Camzyos |
| Medicomp INC | $30.95 | 2022 | |
| Scpharmaceuticals INC. | $29.30 | 2023 | |
| Edwards Lifesciences Corporation | $22.96 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Irhythm Technologies, INC. | $20.38 | 2019 | |
| Alnylam Pharmaceuticals INC. | $17.09 | 2023 | Onpattro |
| Chiesi USA, INC. | $17.03 | 2021 | |
| Philips North America LLC | $14.89 | 2023 | |
| Inspire Medical Systems, INC. | $14.88 | 2023 | Inspire |
| Gilead Sciences, INC. | $13.30 | 2019 | |
| Elutia, INC. | $12.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bunda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.